Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
42.89
+0.60 (+1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via
Benzinga
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
July 24, 2024
Via
Benzinga
3 Growth Stocks No One Is Watching (But They Should Be)
July 11, 2024
While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential.
Via
InvestorPlace
The Latest Analyst Ratings for Protagonist Therapeutics
November 03, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
September 25, 2023
Via
Benzinga
Expert Ratings for Protagonist Therapeutics
July 06, 2023
Via
Benzinga
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
The 3 Best Biotech Stocks to Buy in June 2024
June 05, 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.
Via
InvestorPlace
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
February 01, 2024
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
June 12, 2023
Via
Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
June 09, 2023
Via
Talk Markets
Protagonist Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
April 27, 2023
Via
Benzinga
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
July 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
July 13, 2023
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.
Via
InvestorPlace
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
July 06, 2023
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,
Via
Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
July 06, 2023
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...
Via
Benzinga
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
July 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 03, 2023
Via
Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 03, 2023
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.
Via
Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
US Stocks Mixed; Dow Falls Over 50 Points
July 03, 2023
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...
Via
Benzinga
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
May 12, 2023
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of
Via
Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
May 05, 2023
The company is targeting psoriasis with a first-ever mechanism that could rival leaders.
Via
Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
April 20, 2023
The company's lead pipeline candidate is making news.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.